May 16, 2008
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
DELAWARE | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
ITEM 7.01. Regulation FD Disclosure
On May 16, 2008, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) an industry leader in oncology testing, announced the commercial launch of an assay for detecting the presence of key tissue markers in prostate cancer, including the methylated version of the GST-Pi gene. LabCorp is the first full-service, national clinical laboratory in the U.S. to launch this assay, the first commercially available methylation assay for prostate cancer. The technology was licensed from Veridex, LLC.
Exhibits
99.1 Press Release dated May 16, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Laboratory Corporation of America Holdings (Registrant) |
||||
Date: May 16, 2008 | By: | /s/Bradford T. Smith | ||
Bradford T. Smith, Executive Vice President and Secretary |
||||